Intercept Pharmaceuticals Announces Publication of Study Demonstrating Its Lead
- Intercept Pharmaceuticals Announces Publication of Study Demonstrating Its Lead Compound Can Reverse Liver Fibrosis
Thursday August 12, 9:01 am ET
- Proof-of-Principle Study Published in Gastroenterology -
NEW YORK, Aug. 12 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases, today announced publication in Gastroenterology of a major set of studies led by its scientific co-founder, Stefano Fiorucci, M.D., demonstrating that Intercept's lead FXR agonist, INT-747, can stop development of, and perhaps even reverse, liver fibrosis in animal models.
[Non-text portions of this message have been removed]